Literature DB >> 28185171

Neprilysin Inhibitors in Cardiovascular Disease.

Guson Kang1, Dipanjan Banerjee2.   

Abstract

Mortality from heart failure remains high despite advances in medical therapy over the last three decades. Angiotensin receptor-neprilysin inhibitor (ARNI) combinations are the latest addition to the heart failure medical armamentarium, which is built on the cornerstone regimen of beta blockers, angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers, and aldosterone antagonists. Recent trial data have shown a significant mortality benefit from ARNIs, which, as of May 2016, have now received a class I recommendation for use in patients with heart failure and reduced ejection fraction from the major American and European cardiology societies.

Entities:  

Keywords:  Heart failure; LCZ696; Neprilysin inhibitor; Sacubitril

Mesh：

Substances：

Year:  2017        PMID： 28185171     DOI： 10.1007/s11886-017-0827-0

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  18 in total

1.  Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators.

Authors:  J G Cleland; K Swedberg
Journal:  Lancet       Date:  1998-05-30       Impact factor: 79.321

2.  Effect of nesiritide in patients with acute decompensated heart failure.

Authors:  C M O'Connor; R C Starling; A F Hernandez; P W Armstrong; K Dickstein; V Hasselblad; G M Heizer; M Komajda; B M Massie; J J V McMurray; M S Nieminen; C J Reist; J L Rouleau; K Swedberg; K F Adams; S D Anker; D Atar; A Battler; R Botero; N R Bohidar; J Butler; N Clausell; R Corbalán; M R Costanzo; U Dahlstrom; L I Deckelbaum; R Diaz; M E Dunlap; J A Ezekowitz; D Feldman; G M Felker; G C Fonarow; D Gennevois; S S Gottlieb; J A Hill; J E Hollander; J G Howlett; M P Hudson; R D Kociol; H Krum; A Laucevicius; W C Levy; G F Méndez; M Metra; S Mittal; B-H Oh; N L Pereira; P Ponikowski; W H W Tang; W H Wilson; S Tanomsup; J R Teerlink; F Triposkiadis; R W Troughton; A A Voors; D J Whellan; F Zannad; R M Califf
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

3.  Neprilysin inhibition--a novel therapy for heart failure.

Authors:  Mariell Jessup
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

4.  Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.

Authors:  Kazuomi Kario; Ningling Sun; Fu-Tien Chiang; Ouppatham Supasyndh; Sang Hong Baek; Akiko Inubushi-Molessa; Ying Zhang; Hiromi Gotou; Martin Lefkowitz; Jack Zhang
Journal:  Hypertension       Date:  2014-01-20       Impact factor: 10.190

5.  2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  J Am Coll Cardiol       Date:  2016-05-20       Impact factor: 24.094

6.  SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats.

Authors:  E J Sybertz; P J Chiu; S Vemulapalli; B Pitts; C J Foster; R W Watkins; A Barnett; M F Haslanger
Journal:  J Pharmacol Exp Ther       Date:  1989-08       Impact factor: 4.030

7.  Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study.

Authors:  Noritake Hata; Yoshihiko Seino; Takayoshi Tsutamoto; Shinya Hiramitsu; Noboru Kaneko; Tsutomu Yoshikawa; Hiroyuki Yokoyama; Keiji Tanaka; Kyoichi Mizuno; Jun Nejima; Masahiko Kinoshita
Journal:  Circ J       Date:  2008-09-24       Impact factor: 2.993

8.  The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice.

Authors:  B P Roques; M C Fournié-Zaluski; E Soroca; J M Lecomte; B Malfroy; C Llorens; J C Schwartz
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

9.  Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin.

Authors:  S Ando; M A Rahman; G C Butler; B L Senn; J S Floras
Journal:  Hypertension       Date:  1995-12       Impact factor: 10.190

10.  Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

Authors:  Milton Packer; John J V McMurray; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael Zile; Karl Andersen; Juan Luis Arango; J Malcolm Arnold; Jan Bělohlávek; Michael Böhm; Sergey Boytsov; Lesley J Burgess; Walter Cabrera; Carlos Calvo; Chen-Huan Chen; Andrej Dukat; Yan Carlos Duarte; Andrejs Erglis; Michael Fu; Efrain Gomez; Angel Gonzàlez-Medina; Albert A Hagège; Jun Huang; Tzvetana Katova; Songsak Kiatchoosakun; Kee-Sik Kim; Ömer Kozan; Edmundo Bayram Llamas; Felipe Martinez; Bela Merkely; Iván Mendoza; Arend Mosterd; Marta Negrusz-Kawecka; Keijo Peuhkurinen; Felix J A Ramires; Jens Refsgaard; Arvo Rosenthal; Michele Senni; Antonio S Sibulo; José Silva-Cardoso; Iain B Squire; Randall C Starling; John R Teerlink; Johan Vanhaecke; Dragos Vinereanu; Raymond Ching-Chiew Wong
Journal:  Circulation       Date:  2014-11-17       Impact factor: 29.690
View more
  2 in total

1.  Application and impact of run-in studies.

Authors:  Michael Fralick; Jerry Avorn; Jessica M Franklin; Abdurrahman Abdurrob; Aaron S Kesselheim
Journal:  J Gen Intern Med       Date:  2018-02-15       Impact factor: 5.128

2.  The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three Years of Follow-Up.

Authors:  Shuiqin Cheng; Tingting Zhou; Le Yu; Yunmin Chen; Zhihong Zhang; Jinquan Wang; Yusheng Yu
Journal:  Front Med (Lausanne)       Date:  2022-03-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.